C. Roehrborn

发表

Pathology of benign prostatic hyperplasia

C. Roehrborn, C. Roehrborn, CG Roehrborn, 2008, International Journal of Impotence Research.

AUA guideline on the management of benign prostatic hyperplasia

C. Roehrborn, 2003 .

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.

G. Andriole, C. Roehrborn, K. Slawin, 2004, Urology.

Characterization of prostate size, PSA and endocrine profiles in patients with spinal cord injuries

C. Roehrborn, E. Benaim, S. Litwiller, 1998, Prostate Cancer and Prostatic Diseases.

Improvements in benign prostatic hyperplasia‐specific quality of life with dutasteride, the novel dual 5α‐reductase inhibitor

P. Boyle, G. Andriole, C. Roehrborn, 2003, BJU international.

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review

C. Roehrborn, P. Abrams, C. Roehrborn, 2011, International journal of clinical practice.

Ultrasonography of the kidney

C. Roehrborn, C. Roehrborn, J. Mcconnell, 1992, World Journal of Urology.

Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies

C. Roehrborn, C. Roehrborn, P. V. van Kerrebroeck, 2003 .

Use of electronic medical records to identify patients at risk for prostate cancer in an academic institution

Y. Lotan, C. Roehrborn, D. Bhat, 2011, Prostate Cancer and Prostatic Diseases.

The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

C. Roehrborn, C. G. Roehrborn, 2008, International Journal of Impotence Research.

The potential of serum prostate‐specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia

C. Roehrborn, C. Roehrborn, 2004, BJU international.

Do baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil?

C. Roehrborn, G. Wittert, K. McVary, 2015, Andrology.

Consensus statement: the role of prostate‐specific antigen in managing the patient with benign prostatic hyperplasia

C. Roehrborn, J. Isaacs, J. Schalken, 2004, BJU international.

Prevalence of BPH and lower urinary tract symptoms in West Africans

R. Hoover, K. Yu, I. Thompson, 2011, Prostate Cancer and Prostatic Diseases.

Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians

Y. Lotan, C. Roehrborn, Y Lotan, 2002, Prostate Cancer and Prostatic Diseases.